Cell and Gene Therapy Companies Leverage GenScript's cGMP sgRNA Capability to Accelerate Speed to Market
PISCATAWAY, N.J., Dec. 15, 2022 /PRNewswire/ -- GenScript USA Inc., the world's leading life-science service provider, recently expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies. GenScript's 400,000 square-foot cGMP facility enables next-generation gene and cell therapy R&D programs to advance IND filings and clinical trials.
- GenScript's 400,000 square-foot cGMP facility enables next-generation gene and cell therapy R&D programs to advance IND filings and clinical trials.
- BRL-201 was developed using Quikin CART, BRL's non-viral site-specific integration platform, which can produce CAR-T cell products using one-step, non-viral preparation.
- Earlier this year, another China-based cell therapy company also utilized GenScript's cGMP sgRNA capability and received IND clearance for an autologous hematopoietic stem-cell gene-editing therapy.
- GenScript is committed to advancing non-viral gene and cell therapy development by providing cGMP materials that meet our clients' demanding timelines."